CGT Catapult & CTM CRC sign agreement to advance T-cell scaffold technology


May 25, 2016 / News & Media Releases

UK’s Cell and Gene Therapy Catapult and the Australian CRC for Cell Therapy Manufacturing sign new agreement to advance scaffold technology for commercial production of T-cells. The Cell and Gene Therapy Catapult (CGT) and the CRC for Cell Therapy Manufacturing (CTM CRC), the Australian centre for translation of cell therapy technologies, have announced a project to test at scale CTM CRC’s patented scaffold technology.

Read More